Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb 28;12(2):221-225.
doi: 10.21037/tcr-22-2827. Epub 2023 Feb 1.

The role of bronchoscopy as a novel approach in preoperative lung marking for early-stage lung cancer

Kyle Potts  1 , Nakul Ravikumar  1 , D Kyle Hogarth  1 , Ajay Wagh  1
Affiliations
Editorial

The role of bronchoscopy as a novel approach in preoperative lung marking for early-stage lung cancer

Kyle Potts et al. Transl Cancer Res. .
No abstract available

Keywords: Bronchoscopy; dye marking; early-stage lung cancer; fiducial markers; lung marking.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-2827/coif). DKH reports that he is a stock option holder/stockholder of Body Vision, Broncus, Eolo, Eon, Gravitas, Imbio, Lanier, Magnisity, Noah Medical, LX-Medical, Med-Opsys, Monogram Orthopedics, Preora, Preview Med, Prothea-X, Ryme, Ruby Robotics, Spesana, and VIDA. He is consultant within last 3 years for Alpha Sights, Ambu, Atheneum, Auris, BioPlusRx, Body Vision, Boston Scientific, Broncus, Coleman, CSL, Deerfield, Eolo, Fluidda, Gala, Gilman Capital, GLG, Grand Rounds, Guidepoint Global, Imbio, InhibRx, J&J, Lanier, Level-Ex, Magnisity, MediFind, Morgan-Stanley, Mosaic, Noah Medical, NovaScan, Olympus (Spiration), Oncocyte, Patients Like Me, Preora, Preview Med, Prothea-X, PulmonX, Qure.ai, Ryme, Ruby Robotics, Serpex, Spesana, Takeda, TSC, Veracyte, Volv, and Wave Life Sciences. He reports Research Dollars/Contracted Research (past 3 years and present) from Gala, Nuvaira, Olympus (Spiration), and PulmonX. He was a DSMB member in the past and was on board of InhibRx. He reports lectures given (honoraria received) within the last 3 years for Astra-Zeneca, Biodesix, B.I., Boston Scientific, Genentech, Grifols, PulmonX, Spiration (Olympus), and Takeda. AW has been a consultant for Noah Medical, Medtronic, and Ambu. He is a Speaker for Biodesix. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Example of navigational bronchoscopy procedure used to place fiducial markers. Bronchoscope (orange arrow) with extended working channel (yellow arrow) using fluoroscopy was utilized to place 3 fiducial markers (blue arrow) to localize left lung nodule (blue star).
Figure 2
Figure 2
Intraoperative pictures of a small nodule that was pre-operatively marked with indigo carmine. ENB, AF, and r-EBUS were utilized to safely navigate to the periphery of the lung for dye marking. (A) Thoracoscopic view of pleural dye marking in 1 area. (B) Thoracoscopic view of graspers at alternate dye marked area. (C) Resected dye marked area. ENB, electromagnetic navigation bronchoscopy; AF, augmented fluoroscopy; r-EBUS, radial endobronchial ultrasound.
See this image and copyright information in PMC

Comment on

References

    1. Wang M, Zhang Z, Mei P, et al. Comparison of bronchial methylene blue staining and modified inflation-deflation method in identifying the intersegmental plane during lung segmentectomy. Transl Cancer Res 2022;11:4000-8. 10.21037/tcr-22-1428 - DOI - PMC - PubMed
    1. Krist AH, Davidson KW, et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021;325:962-70. 10.1001/jama.2021.1117 - DOI - PubMed
    1. Landy R, Young CD, Skarzynski M, et al. Using Prediction Models to Reduce Persistent Racial and Ethnic Disparities in the Draft 2020 USPSTF Lung Cancer Screening Guidelines. J Natl Cancer Inst 2021;113:1590-4. 10.1093/jnci/djaa211 - DOI - PMC - PubMed
    1. Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet 2022;399:1607-17. 10.1016/S0140-6736(21)02333-3 - DOI - PubMed
    1. Altorki NK, Wang X, Wigle D, et al. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med 2018;6:915-24. 10.1016/S2213-2600(18)30411-9 - DOI - PMC - PubMed